These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 32380039)

  • 1. Epithelial cell -derived microvesicles: A safe delivery platform of CRISPR/Cas9 conferring synergistic anti-tumor effect with sorafenib.
    He C; Jaffar Ali D; Xu H; Kumaravel S; Si K; Li Y; Sun B; Ma J; Xiao Z
    Exp Cell Res; 2020 Jul; 392(2):112040. PubMed ID: 32380039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microvesicles mediate sorafenib resistance in liver cancer cells through attenuating p53 and enhancing FOXM1 expression.
    Jaffar Ali D; He C; Xu H; Kumaravel S; Sun B; Zhou Y; Liu R; Xiao Z
    Life Sci; 2021 Apr; 271():119149. PubMed ID: 33549596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer-derived exosomes as a delivery platform of CRISPR/Cas9 confer cancer cell tropism-dependent targeting.
    Kim SM; Yang Y; Oh SJ; Hong Y; Seo M; Jang M
    J Control Release; 2017 Nov; 266():8-16. PubMed ID: 28916446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy of sorafenib with mesenchymal stem cells as a novel cancer treatment regimen in xenograft models of hepatocellular carcinoma.
    Seyhoun I; Hajighasemlou S; Muhammadnejad S; Ai J; Nikbakht M; Alizadeh AA; Hosseinzadeh F; Mirmoghtadaei M; Seyhoun SM; Verdi J
    J Cell Physiol; 2019 Jun; 234(6):9495-9503. PubMed ID: 30362607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-delivery of Sorafenib and CRISPR/Cas9 Based on Targeted Core-Shell Hollow Mesoporous Organosilica Nanoparticles for Synergistic HCC Therapy.
    Zhang BC; Luo BY; Zou JJ; Wu PY; Jiang JL; Le JQ; Zhao RR; Chen L; Shao JW
    ACS Appl Mater Interfaces; 2020 Dec; 12(51):57362-57372. PubMed ID: 33301289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
    Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
    J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Combinatorial CRISPR-Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment.
    Xu F; Tong M; Tong CSW; Chan BKC; Chu HY; Wong TL; Fong JHC; Cheung MSH; Mak KH; Pardeshi L; Huang Y; Wong KH; Choi GCG; Ma S; Wong ASL
    Cancer Res; 2021 Dec; 81(24):6219-6232. PubMed ID: 34666996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human liver stem cell-derived microvesicles inhibit hepatoma growth in SCID mice by delivering antitumor microRNAs.
    Fonsato V; Collino F; Herrera MB; Cavallari C; Deregibus MC; Cisterna B; Bruno S; Romagnoli R; Salizzoni M; Tetta C; Camussi G
    Stem Cells; 2012 Sep; 30(9):1985-98. PubMed ID: 22736596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
    Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
    Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma.
    Lin HH; Feng WC; Lu LC; Shao YY; Hsu CH; Cheng AL
    Cancer Lett; 2016 Oct; 381(1):58-66. PubMed ID: 27431312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gold nanoparticles-loaded anti-miR221 enhances antitumor effect of sorafenib in hepatocellular carcinoma cells.
    Cai H; Yang Y; Peng F; Liu Y; Fu X; Ji B
    Int J Med Sci; 2019; 16(12):1541-1548. PubMed ID: 31839741
    [No Abstract]   [Full Text] [Related]  

  • 12. CRISPR/Cas9-mediated genome engineering of CXCR4 decreases the malignancy of hepatocellular carcinoma cells in vitro and in vivo.
    Wang X; Zhang W; Ding Y; Guo X; Yuan Y; Li D
    Oncol Rep; 2017 Jun; 37(6):3565-3571. PubMed ID: 28498420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IQGAP1 gene silencing induces apoptosis and decreases the invasive capacity of human hepatocellular carcinoma cells.
    Zoheir KM; Abd-Rabou AA; Harisa GI; Kumar A; Ahmad SF; Ansari MA; Abd-Allah AR
    Tumour Biol; 2016 Oct; 37(10):13927-13939. PubMed ID: 27488117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel multitarget kinase inhibitor BZG with potent anticancer activity in vitro and vivo enhances efficacy of sorafenib through PI3K pathways in hepatocellular carcinoma cells.
    Wang L; Zhan Y; Wu Z; Lin M; Jin X; Jiang L; Qiu Y
    Biomed Pharmacother; 2020 May; 125():110033. PubMed ID: 32187962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
    Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1α.
    Xu H; Zhao L; Fang Q; Sun J; Zhang S; Zhan C; Liu S; Zhang Y
    PLoS One; 2014; 9(12):e115565. PubMed ID: 25531114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. OATP1B1 Plays an Important Role in the Transport and Treatment Efficacy of Sorafenib in Hepatocellular Carcinoma.
    Wen J; Zhao M
    Dis Markers; 2021; 2021():9711179. PubMed ID: 34721737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-delivery of sorafenib and VEGF-siRNA via pH-sensitive liposomes for the synergistic treatment of hepatocellular carcinoma.
    Yao Y; Wang T; Liu Y; Zhang N
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):1374-1383. PubMed ID: 30977418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineering of HN3 increases the tumor targeting specificity of exosomes and upgrade the anti-tumor effect of sorafenib on HuH-7 cells.
    He C; Jaffar Ali D; Li Y; Zhu Y; Sun B; Xiao Z
    PeerJ; 2020; 8():e9524. PubMed ID: 33062407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extracellular vesicles engineered with valency-controlled DNA nanostructures deliver CRISPR/Cas9 system for gene therapy.
    Zhuang J; Tan J; Wu C; Zhang J; Liu T; Fan C; Li J; Zhang Y
    Nucleic Acids Res; 2020 Sep; 48(16):8870-8882. PubMed ID: 32810272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.